Narcan Now Available Over-the-counter – What to Know

by Philip Kantor | Sep 5, 2023 | News

Partnership to Save Lives: Harm Reduction Therapeutics to donate 200,000 RiVive™ naloxone doses to Remedy Alliance for free distribution

by Dave Giles | Aug 17, 2023 | News

A new, cheaper naloxone is coming to pharmacy shelves, funded in part by Purdue Pharma’s bankruptcy

by Philip Kantor | Aug 17, 2023 | News

FDA APPROVAL OF RiVIVE™ IS A CRITICAL MILESTONE IN MAKING EMERGENCY TREATMENT OF OPIOID OVERDOSE MORE WIDELY AVAILABLE

by Dave Giles | Aug 1, 2023 | News

Harm Reduction Therapeutics and Catalent Sign Commercial Supply Agreement for Naloxone Nasal Spray

by Philip Kantor | Mar 24, 2023 | News

Harm Reduction Therapeutics Inc. doesn’t have to make an advisory committee presentation for its proposal for an OTC naloxone nasal spray, but still must wait for a US Food and Drug Administration decision it’s confident will be for approval. The FDA on 1 March announced it cancelled the meeting of its Nonprescription Drug and Anesthetic and Analgesic Drug Products advisory committees to consider HRT’s new drug application for a 3-mg naloxone nasal spray scheduled 20 March. “The meeting is no longer needed,” the agency states in the announcement scheduled for publication in the Federal Register on 2 March.

by Philip Kantor | Mar 2, 2023 | News